Gene · 9978
RBX1: ring-box 1
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. RBX1: ring-box 1. Genes, record 9978. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/9978
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P62877 | E3 ubiquitin-protein ligase RBX1 | 108 | 106 | Ensembl, GeneID, HGNC |
Source UniProt
Patents61
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| US 12539325 B2 | 2026-02-03 | 59 | P62877 | Espacenet |
| EP 4679090 A1 | 2026-01-14 | 17 | P62877 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 320 | P62877 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 320 | P62877 | Espacenet |
| WO 2024240908 A1 | 2024-11-28 | 25 | P62877 | Espacenet |
| US 12133879 B2 | 2024-11-05 | 59 | P62877 | Espacenet |
| US 11872193 B2 | 2024-01-16 | 59 | P62877 | Espacenet |
| US 11564998 B2 | 2023-01-31 | 4703 | P62877 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 75133 | P62877 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 178104 | P62877 | Espacenet |
1 to 10 of 61
See all 61 patentsDrugs6
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| IBERDOMIDE | CHEMBL3989927 | CRL4(CRBN) E3 ubiquitin ligase modulator | MODULATOR | ChEMBL |
| LENALIDOMIDE | CHEMBL848 | CRL4(CRBN) E3 ubiquitin ligase inhibitor | INHIBITOR | ChEMBL |
| LENALIDOMIDE | CHEMBL848 | CRL4(CRBN) E3 ubiquitin ligase modulator | MODULATOR | ChEMBL |
| LENALIDOMIDE HYDROCHLORIDE MONOHYDRATE | CHEMBL6068337 | CRL4(CRBN) E3 ubiquitin ligase modulator | MODULATOR | ChEMBL |
| POMALIDOMIDE | CHEMBL43452 | CRL4(CRBN) E3 ubiquitin ligase inhibitor | INHIBITOR | ChEMBL |
| THALIDOMIDE | CHEMBL468 | CRL4(CRBN) E3 ubiquitin ligase inhibitor | INHIBITOR | ChEMBL |
Trials1,695
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07605416 | LENALIDOMIDE | PHASE2 | ClinicalTrials.gov | |
| NCT07601100 | IBERDOMIDE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07600151 | LENALIDOMIDE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07585747 | LENALIDOMIDE | PHASE2 | ClinicalTrials.gov | |
| NCT07569757 | POMALIDOMIDE | PHASE3 | ClinicalTrials.gov | |
| NCT07562022 | LENALIDOMIDE | PHASE3 | ClinicalTrials.gov | |
| NCT07555938 | POMALIDOMIDE | PHASE3 | ClinicalTrials.gov | |
| NCT07532525 | POMALIDOMIDE | PHASE1 | ClinicalTrials.gov | |
| NCT07523737 | POMALIDOMIDE | PHASE2 | ClinicalTrials.gov | |
| NCT07505849 | LENALIDOMIDE | PHASE2 | ClinicalTrials.gov |
1 to 10 of 1,695
See all 1,695 trialsNIH grants2,387
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | RBX1 papers | Newest fiscal year |
|---|---|---|---|
| P30CA021765 | Cancer Center Support Grant (CCSG) | 29 | 2025 |
| P30ES006694 | Southwest Environmental Health Sciences Center | 24 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 23 | 2025 |
| R01AG011085 | Ubiquitin‐mediated proteolysis and cell cycle control | 22 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 15 | 2025 |
| R01CA214608 | The molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase | 14 | 2025 |
| P30CA016087 | Cancer Center Support Grant | 13 | 2025 |
| R01HL096376 | E3 Ligase-Mediated Immunosuppression in Acute Lung Injury | 13 | 2025 |
| R01HL097376 | Sepsis-Associated Immune Suppression and F-box Proteins | 13 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 10 | 2025 |
1 to 10 of 2,387Source NIH's project files
See all 2,387 nih grantsPapers3,762
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| HSP90 shields ROC1/RBX1 from proteasomal degradation by CHIP E3 ubiquitin ligase to promote lung adenocarcinoma. | Signal Transduct Target Ther | 2026 | 42764310 | PubTator, text mining | PubMed |
| DH-AUTAC induces ferroptosis in colorectal cancer by targeting DHODH for autophagic degradation through KCTD10-SQSTM1 signaling. | J Gastroenterol | 2026 | 42622824 | PubTator, text mining | PubMed |
| Recent advances in etiology and treatment of von Hippel-Lindau Disease (VHLD). | Cancer Metastasis Rev | 2026 | 42593521 | PubTator, text mining | PubMed |
| Circadian Regulation of Glucose Metabolism: Implications for Pathogenesis and Chronotherapy of Type 2 Diabetes. | Diabetology (Basel) | 2026 | 42583078 | PubTator, text mining | PubMed |
| Neddylation pathway promotes the ubiquitinated degradation of FBXO21 in lung cancer cells. | Carcinogenesis | 2026 | 42555346 | PubTator, text mining | PubMed |
| Neddylation of NFATc1 and Runx2 regulates osteoclast-osteoblast balance and represents a dual-action therapeutic target for postmenopausal osteoporosis. | Exp Mol Med | 2026 | 42543398 | PubTator, text mining | PubMed |
| African swine fever virus pMGF360-3 L suppresses innate immunity by facilitating CMA-dependent SKP1 degradation to promote BNIP3-mediated mitophagy. | Autophagy | 2026 | 42543005 | PubTator, text mining | PubMed |
| Alphavirus M1 disrupts super-enhancer-driven oncogenic transcription via non-structural protein NSP2 in osteosarcoma. | Nat Commun | 2026 | 42386745 | PubTator, text mining | PubMed |
| TDTAC: a generalized time-dependent torsion angle correlation framework for resolving directional coordination in large biomolecular assemblies. | Front Mol Biosci | 2026 | 42311447 | PubTator, text mining | PubMed |
| Structure of the E3 ligase CRL2ZYG11B with substrates reveals the molecular basis for N-degron recognition and ubiquitination. | Cell Rep | 2026 | 42224082 | PubTator, text mining | PubMed |
1 to 10 of 3,762
See all 3,762 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/9978
GET https://conductscience.org/api/genes/v1/9978/patents?page=2